Recent changes of invasive meningococcal disease in France: arguments to revise the vaccination strategy in view of those of other countries

References

• Christensen H, May M, Bowen L, Hickman M, Trotter CL. Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect Dis. 2010;10:853–61. doi:10.1016/S1473-3099(10)70251-6.
   PubMed Web of Science ®Google Scholar
• Bazan JA, Turner AN, Kirkcaldy RD, Retchless AC, Kretz CB, Briere E, Tzeng Y-L, Stephens DS, Maierhofer C, Del Rio C, et al. Large cluster of neisseria meningitidis urethritis in columbus, Ohio, 2015. Clin Infect Dis. 2017;65:92–99. doi:10.1093/cid/cix215.
   PubMed Web of Science ®Google Scholar
• Acevedo R, Bai X, Borrow R, Caugant DA, Carlos J, Ceyhan M, Christensen H, Climent Y, De Wals P, Dinleyici EC, et al. The global meningococcal initiative meeting on prevention of meningococcal disease worldwide: epidemiology, surveillance, hypervirulent strains, antibiotic resistance and high-risk populations. Expert Rev Vaccines. 2019;18:15–30. doi:10.1080/14760584.2019.1557520.
   PubMed Web of Science ®Google Scholar
• Rosain J, Hong E, Fieschi C, Martins PV, El Sissy C, Deghmane AE, Ouachée M, Thomas C, Launay D, de Pontual L, et al. Strains responsible for invasive meningococcal disease in patients with terminal complement pathway deficiencies. J Infect Dis. 2017;215:1331–38. doi:10.1093/infdis/jix143.
   PubMed Web of Science ®Google Scholar
• Viner RM, Booy R, Johnson H, Edmunds WJ, Hudson L, Bedford H, Kaczmarski E, Rajput K, Ramsay M, Christie D. Outcomes of invasive meningococcal serogroup B disease in children and adolescents (MOSAIC): a case-control study. Lancet Neurol. 2012;11:774–83. doi:10.1016/S1474-4422(12)70180-1.
   PubMed Web of Science ®Google Scholar
• Parent du Chatelet I, Deghmane AE, Antona D, Hong E, Fonteneau L, Taha MK, Levy-Bruhl D. Characteristics and changes in invasive meningococcal disease epidemiology in France, 2006–2015. J Infect. 2017;74:564–74.
   PubMed Web of Science ®Google Scholar
• Caron F, du Chatelet IP, Leroy JP, Ruckly C, Blanchard M, Bohic N, Massy N, Morer I, Floret D, Delbos V, et al. From tailor-made to ready-to-wear meningococcal B vaccines: longitudinal study of a clonal meningococcal B outbreak. Lancet Infect Dis. 2011;11:455–63. doi:10.1016/S1473-3099(11)70027-5.
   PubMed Web of Science ®Google Scholar
• Broker M, Jacobsson S, Kuusi M, Pace D, Simoes MJ, Skoczynska A, Taha M-K, Toropainen M, Tzanakaki G. Meningococcal serogroup Y emergence in Europe: update 2011. Hum Vaccin Immunother. 2012;8:1907–11. doi:10.4161/hv.21794.
   PubMed Web of Science ®Google Scholar
• Hong E, Barret AS, Terrade A, Denizon M, Antona D, Aouiti-Trabelsi M, Deghmane AE, Parent du Chatelet I, Levy-Bruhl D, Taha MK. Clonal replacement and expansion among invasive meningococcal isolates of serogroup W in France. J Infect. 2018;76:149–58. doi:10.1016/j.jinf.2017.10.015.
   PubMed Web of Science ®Google Scholar
• Guiddir T, Gros M, Hong E, Terrade A, Denizon M, Deghmane AE, Taha M-K. Unusual initial abdominal presentations of invasive meningococcal disease. Clin Infect Dis. 2018;67:1220–27. doi:10.1093/cid/ciy257.
   PubMed Web of Science ®Google Scholar
• Krone M, Gray S, Abad R, Skoczynska A, Stefanelli P, van der Ende A, Tzanakaki G, Mölling P, João Simões M, Křížová P, et al. Increase of invasive meningococcal serogroup W disease in Europe, 2013 to 2017. Euro Surveill. 2019;24. doi:10.2807/1560-7917.ES.2019.24.14.1800245
   PubMedGoogle Scholar
• Knol MJ, Hahne SJM, Lucidarme J, Campbell H, de Melker HE, Gray SJ, Borrow R, Ladhani SN, Ramsay ME, van der Ende A, et al. Temporal associations between national outbreaks of meningococcal serogroup W and C disease in the Netherlands and England: an observational cohort study. Lancet Public Health. 2017;2:e473–e82. doi:10.1016/S2468-2667(17)30157-3.
   PubMed Web of Science ®Google Scholar
• Khatami A, Snape MD, Davis E, Layton H, John T, Yu LM, Dull PM, Gill CJ, Odrjlin T, Dobson S, et al. Persistence of the immune response at 5 years of age following infant immunisation with investigational quadrivalent MenACWY conjugate vaccine formulations. Vaccine. 2012;30:2831–38. doi:10.1016/j.vaccine.2012.02.046.
   PubMed Web of Science ®Google Scholar
• HCSP. Avis relatif à la vaccination par le vaccin méningococcique conjugué de sérogroupe C. 2009. [accessed 2019 Dec 15]. www.hcsp.fr/explore.cgi/hcspa20090424_meningC.pdf.
   Google Scholar
• Larson HJ, de Figueiredo A, Xiahong Z, Schulz WS, Verger P, Johnston IG, Cook AR, Jones NS. The State of Vaccine Confidence 2016: global insights through a 67-country survey. EBioMedicine. 2016;12:295–301. doi:10.1016/j.ebiom.2016.08.042.
   PubMed Web of Science ®Google Scholar
• Bassi C, Taha MK, Merle C, Hong E, Levy-Bruhl D, Barret AS, Mounchetrou Njoya I. A cluster of invasive meningococcal disease (IMD) caused by Neisseria meningitidis serogroup W among university students, France, February to May 2017. Euro Surveill. 2017;22. doi:10.2807/1560-7917.ES.2017.22.28.30574.
   PubMedGoogle Scholar
• Barret AS, Clinard F, Taha MK, Girard I, Hong E, Tessier S, Zurbaran M, de Bort C, Antona D, Deghmane AE, et al. Cluster of serogroup W invasive meningococcal disease in a university campus. Med Mal Infect. 2019. doi:10.1016/j.medmal.2019.10.003.
   PubMed Web of Science ®Google Scholar
• McNeil LK, Donald RGK, Gribenko A, French R, Lambert N, Harris SL, Jones TR, Li S, Zlotnick G, Vogel U, et al. Predicting the susceptibility of meningococcal serogroup B isolates to bactericidal antibodies elicited by bivalent rLP2086, a novel prophylactic vaccine. MBio. 2018;9. doi:10.1128/mBio.00036-18
   Web of Science ®Google Scholar
• Vogel U, Taha MK, Vazquez JA, Findlow J, Claus H, Stefanelli P, Caugant DA, Kriz P, Abad R, Bambini S, et al. Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment. Lancet Infect Dis. 2013;13:416–25. doi:10.1016/S1473-3099(13)70006-9.
   PubMed Web of Science ®Google Scholar
• Read RC, Baxter D, Chadwick DR, Faust SN, Finn A, Gordon SB, Heath PT, Lewis DJM, Pollard AJ, Turner DPJ, et al. Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial. Lancet. 2014;384:2123–31. doi:10.1016/S0140-6736(14)60842-4.
   PubMed Web of Science ®Google Scholar
• Soeters HM, Whaley M, Alexander-Scott N, Kanadanian KV, MacNeil JR, Martin SW, McNamara LA, Sicard K, Vanner C, Vuong J, et al. Meningococcal carriage evaluation in response to a serogroup B meningococcal disease outbreak and mass vaccination campaign at a College-Rhode Island, 2015–2016. Clin Infect Dis. 2017;64:1115–22. doi:10.1093/cid/cix091.
   PubMed Web of Science ®Google Scholar
• McQuaid F, Snape MD, John TM, Kelly S, Robinson H, Yu LM, Toneatto D, D’Agostino D, Dull PM, Pollard AJ, et al. Persistence of specific bactericidal antibodies at 5 years of age after vaccination against serogroup B meningococcus in infancy and at 40 months. CMAJ. 2015;187:E215–23. doi:10.1503/cmaj.141200.
   PubMed Web of Science ®Google Scholar
• Marshall HS, Richmond PC, Beeslaar J, Jiang Q, Jansen KU, Garces-Sanchez M, Martinón-Torres F, Szenborn L, Wysocki J, Eiden J, et al. Meningococcal serogroup B-specific responses after vaccination with bivalent rLP2086: 4 year follow-up of a randomised, single-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis. 2017;17:58–67. doi:10.1016/S1473-3099(16)30314-0.
   PubMed Web of Science ®Google Scholar
• Parikh SR, Andrews NJ, Beebeejaun K, Campbell H, Ribeiro S, Ward C, White JM, Borrow R, Ramsay ME, Ladhani SN, et al. Effectiveness and impact of a reduced infant schedule of 4CMenB vaccine against group B meningococcal disease in England: a national observational cohort study. Lancet. 2016;388:2775–82. doi:10.1016/S0140-6736(16)31921-3.
   PubMed Web of Science ®Google Scholar
• HCSP. Avis du HCSP relatif à l’utilisation du vaccin Bexsero (Novartis Vaccines and Diagnostics). 2013. [accessed 2019 Dec 15]. http://www.hcsp.fr/Explore.cgi/Telecharger?NomFichier=hcspa20131025_vaccmeningocoqueBBexsero.pdf.
   Google Scholar
• Vygen S, Hellenbrand W, Stefanoff P, Hanquet G, Heuberger S, Stuart J. European public health policies for managing contacts of invasive meningococcal disease cases better harmonised in 2013 than in 2007. Euro Surveill. 2016;21:23–31. doi:10.2807/1560-7917.ES.2016.21.5.30125.
   PubMedGoogle Scholar
• Sharma K, Chiu C, Wood N. Meningococcal vaccines in Australia: a 2019 update. Aust Prescr. 2019;42:131–35. doi:10.18773/austprescr.2019.042.
   PubMed Web of Science ®Google Scholar
• Taha MK, Deghmane AE, Knol M, van der Ende A. Whole genome sequencing reveals Trans-European spread of an epidemic Neisseria meningitidis serogroup W clone. Clin Microbiol Infect. 2019;25:765–67. doi:10.1016/j.cmi.2018.12.030.
   PubMed Web of Science ®Google Scholar
• Oldfield NJ, Green LR, Parkhill J, Bayliss CD, Turner DPJ. Limited impact of adolescent meningococcal ACWY vaccination on neisseria meningitidis serogroup W carriage in University Students. J Infect Dis. 2018;217:608–16. doi:10.1093/infdis/jix596.
   PubMed Web of Science ®Google Scholar
• Sall O, Stenmark B, Glimaker M, Jacobsson S, Molling P, Olcen P, FREDLUND H. Clinical presentation of invasive disease caused by Neisseria meningitidis serogroup Y in Sweden, 1995 to 2012. Epidemiol Infect. 2017;145:2137–43. doi:10.1017/S0950268817000929.
   PubMed Web of Science ®Google Scholar
• Vienne P, Ducos-Galand M, Guiyoule A, Pires R, Giorgini D, Taha MK, Alonso J-M. The role of particular strains of Neisseria meningitidis in meningococcal arthritis, pericarditis, and pneumonia. Clin Infect Dis. 2003;37:1639–42. doi:10.1086/379719.
   PubMed Web of Science ®Google Scholar
• Feldman C, Anderson R. Meningococcal pneumonia: a review. Pneumonia. 2019;11:3. doi:10.1186/s41479-019-0062-0.
   Web of Science ®Google Scholar
• Knuf M, Romain O, Kindler K, Walther U, Tran PM, Pankow-Culot H, Fischbach T, Kieninger-Baum D, Bianco V, Baine Y, et al. Immunogenicity and safety of the quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) in 2-10-year-old children: results of an open, randomised, controlled study. Eur J Pediatr. 2013;172:601–12. doi:10.1007/s00431-012-1924-0.
   PubMed Web of Science ®Google Scholar
• Bryan P, Seabroke S, Wong J, Donegan K, Webb E, Goldsmith C, Vipond C, Feavers I. Safety of multicomponent meningococcal group B vaccine (4CMenB) in routine infant immunisation in the UK: a prospective surveillance study. Lancet Child Adolesc Health. 2018;2:395–403. doi:10.1016/S2352-4642(18)30103-2.
   PubMedGoogle Scholar